MicroRNA prognostic markers for immune checkpoint inhibitor success in urologic cancers.

IF 2.3 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-03-10 DOI:10.1080/1750743X.2026.2640756

Panagiotis J Vlachostergios, Konstatinos Evmorfopoulos, Konstantinos Marsitopoulos, Ioannis Tamposis, Maria Samara, Eleni Thodou, Panagiotis Sarantis, Dimitrios Matthaios, Michalis V Karamouzis, Vassilios Tzortzis, Antonis Giakountis

{"title":"MicroRNA prognostic markers for immune checkpoint inhibitor success in urologic cancers.","authors":"Panagiotis J Vlachostergios, Konstatinos Evmorfopoulos, Konstantinos Marsitopoulos, Ioannis Tamposis, Maria Samara, Eleni Thodou, Panagiotis Sarantis, Dimitrios Matthaios, Michalis V Karamouzis, Vassilios Tzortzis, Antonis Giakountis","doi":"10.1080/1750743X.2026.2640756","DOIUrl":null,"url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) have significantly transformed the treatment landscape of urologic malignancies, including bladder cancer, renal cell carcinoma (RCC), and prostate cancer. Despite impressive clinical responses in subsets of patients, the heterogeneity of response highlights the urgent need for robust prognostic biomarkers. MicroRNAs (miRNAs) - small non-coding RNAs that regulate gene expression post-transcriptionally - have emerged as pivotal players in tumor immune regulation and cancer progression. This review synthesizes current evidence on miRNA prognostic markers predictive of ICI success in urologic cancers, emphasizing their biological functions, clinical utility, and therapeutic implications. We discuss miRNA signatures with prognostic value, their mechanisms modulating immune checkpoints, and prospects for integrating miRNA profiling into personalized immunotherapy strategies. This work provides the first cancer-type - stratified synthesis linking mechanistic data, circulating biomarkers, and therapeutic modulation on miRNAs and ICIs in urologic cancers.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"99-116"},"PeriodicalIF":2.3000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094240/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2026.2640756","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Immune checkpoint inhibitors (ICIs) have significantly transformed the treatment landscape of urologic malignancies, including bladder cancer, renal cell carcinoma (RCC), and prostate cancer. Despite impressive clinical responses in subsets of patients, the heterogeneity of response highlights the urgent need for robust prognostic biomarkers. MicroRNAs (miRNAs) - small non-coding RNAs that regulate gene expression post-transcriptionally - have emerged as pivotal players in tumor immune regulation and cancer progression. This review synthesizes current evidence on miRNA prognostic markers predictive of ICI success in urologic cancers, emphasizing their biological functions, clinical utility, and therapeutic implications. We discuss miRNA signatures with prognostic value, their mechanisms modulating immune checkpoints, and prospects for integrating miRNA profiling into personalized immunotherapy strategies. This work provides the first cancer-type - stratified synthesis linking mechanistic data, circulating biomarkers, and therapeutic modulation on miRNAs and ICIs in urologic cancers.

查看原文本刊更多论文

免疫检查点抑制剂在泌尿系统癌症中成功的MicroRNA预后标志物。

免疫检查点抑制剂（ICIs）已经显著改变了泌尿系统恶性肿瘤的治疗前景，包括膀胱癌、肾细胞癌（RCC）和前列腺癌。尽管在患者亚群中有令人印象深刻的临床反应，但反应的异质性突出了对可靠的预后生物标志物的迫切需要。MicroRNAs （miRNAs）是一种转录后调节基因表达的小非编码rna，在肿瘤免疫调节和癌症进展中发挥着关键作用。这篇综述综合了目前关于miRNA预后标记物预测泌尿系统肿瘤ICI成功的证据，强调了它们的生物学功能、临床应用和治疗意义。我们讨论了具有预后价值的miRNA特征，它们调节免疫检查点的机制，以及将miRNA分析整合到个性化免疫治疗策略中的前景。这项工作提供了第一个癌症类型分层合成，将机制数据、循环生物标志物和泌尿系统癌症中mirna和ICIs的治疗调节联系起来。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.